102 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining … non-pathogenic signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
for oral delivery.
About Itolizumab
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6 … signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells
8-K
EX-99.1
incne8r px2k2
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.2
dqqwletvv
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.1
ziotk
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.1
fu288ellj1mijt
16 Oct 23
Regulation FD Disclosure
8:05am
424B5
c2m88m
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
2b4q 4mge7
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
sei7my i487zx
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
8-K
EX-99.1
4uo55 etsxonwts0c
23 Dec 22
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
4:11pm
425
p82t60urot0gzfh
6 Dec 22
Business combination disclosure
7:02am
8-K
EX-99.1
0e6vbdhdq0ysg4i
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
425
h55om2xvom
14 Nov 22
Business combination disclosure
4:20pm